The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial
Reveille JD, Hwang MC, Danve A, Kafka S, Peterson S, Lo KH, Kim L, Hsia EC, Chan EKH, Deodhar A. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. Clinical Rheumatology 2020, 40: 1331-1341. PMID: 32926247, DOI: 10.1007/s10067-020-05342-7.Peer-Reviewed Original ResearchConceptsHealth-related qualityDisease activityWeek 52Work Limitations QuestionnaireIntravenous golimumabWeeks 0Week 16Functioning outcomesEQ-5D-5L indexPlacebo-crossover groupProductivity loss scoresEffective treatment optionVisual analog scaleConclusionsIn patientsPlacebo groupSpondylitis QualityAdult patientsAnalog scaleEQ-VASWeek 28Treatment optionsProductivity outcomesWeek 8GolimumabHRQoLManaging rheumatic diseases during COVID-19
Ladani AP, Loganathan M, Danve A. Managing rheumatic diseases during COVID-19. Clinical Rheumatology 2020, 39: 3245-3254. PMID: 32895747, PMCID: PMC7476772, DOI: 10.1007/s10067-020-05387-8.Peer-Reviewed Original ResearchConceptsAutoimmune rheumatic diseasesRheumatic diseasesImmunosuppressive agentsRheumatology practiceCOVID-19Multisystem autoimmune rheumatic diseaseLong-term complicationsCOVID-19 patientsCoronavirus disease 2019 (COVID-19) pandemicCOVID-19 infectionDisease 2019 pandemicMode of spreadImmunosuppressant managementImmunosuppressant medicationsViral illnessOrgan failureClinical featuresAutoimmune diseasesSerious infectionsTreatment optionsEffective vaccineImmune systemMedicationsDiseasePatients